Skip to main content
. 2022 Apr 6;5:46. doi: 10.1038/s42004-022-00661-z

Fig. 8. In vivo anticancer activity of BSO-OxMal and BSO-OxOAc compared to oxaliplatin.

Fig. 8

Mice bearing CT26 allografts (n = 4 per group) were treated twice a week for two weeks (black arrows) with equimolar concentrations of BSO-OxMal (23.5 mg/kg), BSO-OxOAc (19.1 mg/kg) or oxaliplatin (9 mg/kg). Mean ± SEM (standard error of mean) (a) and individual (b) tumor volumes were assessed at the indicated time points by caliper measurements (maximal tumor growth inhibition of 61.2%, 51.3% and 51.3% at day 11, for BSO-OxMal, BSO-OxOAc and oxaliplatin respectively; tumor doubling time extended by 1.8-fold, 1.2-fold, and 1.3-fold, respectively). (c) Overall survival of mice based on FELASA guidelines was analyzed by Kaplan Meier curves. Statistical significance was tested using one-way ANOVA (a) or Mantel-Cox test (c). In all cases: *p < 0.05; **p < 0.01; ***p < 0.001.